Medical Device Industry Latest News Report (April 23, 2026)

Domestic News: Technological Innovation and Strengthening of Manufacturing Bases

GE Healthcare Japan Launches New Version of Point of Care Ultrasound Diagnostic Device

【Company/Institution】 GE Healthcare Japan Corporation
【Category】 New Products/Technological Innovation

GE Healthcare Japan Corporation began sales of a new version of its Point of Care ultrasound diagnostic device “Venue™” series (Venue, Venue Go, Venue Fit), equipped with AI functions, on April 22, 2026. The newly integrated AI tools include “Nerveblox” to support nerve block procedures, “Auto Bladder Volume” for semi-automatic bladder volume measurement, and “AFI” to automatically track myocardial wall movement for cardiac function assessment. This is expected to further improve examination efficiency and diagnostic quality in departments such as anesthesiology, emergency medicine, and intensive care units.

Point of Care ultrasound is a highly mobile medical device that can provide immediate diagnostic information at the patient's bedside or in emergency settings. The integration of AI functions enables highly accurate diagnoses even by physicians without specialized training, contributing to the standardization of medical quality. Its utilization is particularly anticipated in regions with limited medical resources, such as rural areas and remote islands.

Nakashima Health Force to Invest Approximately 10 Billion Yen in New Metal 3D Printer Factory

【Company/Institution】 Nakashima Health Force Co., Ltd.
【Category】 Manufacturing/Production Base Enhancement

Nakashima Health Force Co., Ltd., a manufacturer of orthopedic medical devices, announced that it will invest approximately 10 billion yen to construct a new headquarters and factory in Akaiwa City, Okayama Prefecture. The company aims to commence operations in December 2027. The new factory will expand its manufacturing floor space to approximately three times that of the current factory by adding state-of-the-art metal 3D printers. This will significantly increase the production capacity for “patient-specific products” tailored to each patient's bone structure, thereby strengthening the future medical infrastructure supply system.

Patient-specific (custom-made) orthopedic implants hold high medical value by addressing complex cases that cannot be managed with standard products. Advances in metal 3D printing technology are leading to reduced manufacturing costs and shorter delivery times, which also contributes to strengthening the competitiveness of domestic manufacturing. Furthermore, the expanded supply of domestically produced products that have obtained manufacturing and marketing approval under the Pharmaceuticals and Medical Devices Act aligns with the policy goal of promoting the domestic production of medical devices.

International News: Q1 2026 Earnings Season Heats Up for Major Companies

Intuitive Surgical Reports 23% Revenue Increase in Q1 Earnings

【Company/Organization】 Intuitive Surgical (USA)
【Category】 Corporate Performance, Technological Innovation

Intuitive Surgical, a global leader in surgical robotics, announced its Q1 2026 earnings, reporting a 23% year-over-year revenue increase to $2.8 billion. The total number of procedures worldwide increased by approximately 17%, with a 16% increase in procedures performed using its flagship “da Vinci” system, and the adoption of the next-generation “da Vinci 5” is progressing. Furthermore, procedures using the “Ion” endoluminal system, which is expected to be utilized in areas such as gastrointestinal endoscopy, showed rapid growth of 39%, indicating the deep penetration of the company's platforms into medical practice.

Intuitive Surgical's strong performance demonstrates the global adoption of surgical robots as a standard tool in surgery. The rapid growth of the “Ion” system, in particular, suggests an acceleration in the application of robotic technology to endoluminal procedures, including the gastrointestinal endoscopy field. This trend is noteworthy for Japanese endoscope manufacturers from both competitive and collaborative perspectives.

Boston Scientific's Q1 Earnings Strong, but Full-Year Guidance Lowered

【Company/Organization】 Boston Scientific (USA)
【Category】 Corporate Performance, Market Trends

Boston Scientific announced its Q1 2026 earnings, reporting a 11.6% year-over-year revenue increase to $5.2 billion, exceeding market expectations. While cardiovascular and endoscopy segments showed robust growth of 13.5% and 9.4% respectively, the company lowered its full-year 2026 adjusted EPS (earnings per share) guidance from the previous $3.43-$3.49 to $3.34-$3.41, considering foreign exchange fluctuations and the impact of certain acquisitions and divestitures. The company stated its continued focus on advancing its innovative pipeline and executing its long-term strategy.

The 9.4% growth in the endoscopy segment indicates continued strong demand in the gastrointestinal endoscopy field. However, the lowering of full-year guidance reiterates that foreign exchange risks and geopolitical uncertainties are impacting the performance of multinational medical device companies, requiring similar risk management from Japanese companies.

Regulatory Trends

FDA Warns of Nitrosamine Impurity Risk in Devices

【Company/Organization】 U.S. Food and Drug Administration (FDA) / Center for Devices and Radiological Health (CDRH)
【Category】 Regulatory Trends・Quality Management

The U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) has issued a warning to manufacturers of drug-device combination products regarding the potential risk of contamination with carcinogenic nitrosamine impurities. Specifically, cases of impurities have been reported in products containing the antibacterial drug “rifampin,” which is used in items such as catheters and antimicrobial envelopes for cardiac implantable devices. The FDA is requesting manufacturers to establish risk assessments and analytical methods for manufacturing processes and storage conditions, and strict compliance will be required for future regulatory submissions and quality management.

Nitrosamines are impurities with suspected carcinogenic properties, and strict control standards have already been established in the pharmaceutical sector. This FDA warning clarifies that similar quality management will be required for drug-device combination products. In Japan, the PMDA may also request similar measures, and manufacturers should promptly conduct risk assessments and consider updating regulatory submission documents as necessary.

---

Impact on the Industry and Future Outlook

This week, leading companies from Japan and the United States successively announced the latest trends in medical devices utilizing cutting-edge technologies such as AI and 3D printing. In particular, the implementation of AI in gastrointestinal endoscopes and ultrasound diagnostic equipment is a critical trend that directly leads to a reduction in the burden on physicians and an improvement in diagnostic accuracy.

Furthermore, regulatory authorities such as PMDA and FDA are promoting the rapid approval of new technologies (e.g., breakthrough designations) while also strengthening their oversight of quality control and safety. Medical device manufacturers are continuously required to optimize their regulatory application processes and establish strict quality assurance systems from manufacturing to post-market surveillance.

References

• GE Healthcare Japan to Launch New Version of Point of Care Ultrasound Diagnostic System “Venue™” Series
• Nakashima Healthforce to Build New Headquarters and Factory in Akaiwa City – Investing Approximately 10 Billion Yen to Expand Metal 3D Printers
• MassDevice: Intuitive sales increase 23% in Q1, da Vinci procedures expected to see double-digit growth in 2026
• MassDevice: Boston Scientific cuts 2026 guidance despite Q1 beats
• Medical Design & Outsourcing: FDA warns device manufacturers of nitrosamine impurities that could cause cancer